Several kinases, such as NTRK1 (10,495th → 29th), FYN (3902nd → 46th), ABL1 (7261st → 91st), and SRC (8965th → 56th), are being studied for repurposing several kinase inhibitors for COVID-19 treatment [37,38]. This evidence concerns the gene SRC and COVID-19.